Skip to main content
SpringerLink
Log in

Ductal Carcinoma In Situ: Systemic Treatment

  • Chapter
Breast Cancer and Molecular Medicine

  • 1016 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Allred DC, Berardo MD, Prosser J, O’Connell P (1997) Biologic and genetic features of in situ breast cancer. In: Ductal Carcinoma In Situ of The Breast, MJ Silverstein, ed. Williams & Wilkins, Baltimore, MD, pp. 39–42

    Google Scholar 

  2. Allred DC, Bryant J, Dignam JJ, et al (2002) Estrogen receptor expression as a predictive marker of effectiveness of tamoxifen in the treatment of DCIS: findings from NSABP Protocol B-24. Breast Cancer Res Treat 76:S36 (abstract)

    Google Scholar 

  3. Allred DC, Mohsin SK, Fuqua SAW (2001) Histological and biological evolution of human premalignant breast disease. Endoc Relat Cancer 8:47–61

    Article  CAS  Google Scholar 

  4. Allred DC, Tsimelzon A, Mohsin SK, Hilsenbeck SG, Medina D, Osborne CK, O’Connell P (2003) Genetic differences between ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res Treat 82(Suppl 1):S10 (abstract 13)

    Google Scholar 

  5. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T; The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802–1810

    Article  PubMed  CAS  Google Scholar 

  6. Bobrow LG, Happerfield LC, Gregory WM, Springall RD, Millis RR (1994) The classification of ductal carcinoma in situ and its association with biological markers. Semin Diagn Pathol 11:199–207

    PubMed  CAS  Google Scholar 

  7. Boland GP, Knox WF, Bundred WJ (2002) Molecular markers and therapeutic targets in ductal carcinoma in situ. Microsc Res Tech 59:3–11

    Article  PubMed  CAS  Google Scholar 

  8. Bordeleau L, Rakovitch E, Nalmark DM, Pritchard KI, Ackerman I, Sawka CA (2001) A comparison of four treatment strategies for ductal carcinoma in situ using decision analysis. Cancer 92:23–29

    Article  PubMed  CAS  Google Scholar 

  9. Bundred NJ, Anderson EA, Gee J, et al (2003) Randomised, double-blind, placebo-controlled trial of short-term effects of gefitinib (Iressa, ZD1839) on ductal carcinoma in situ. Breast Cancer Res Treat 82(Suppl 1):510 (abstract 14)

    Google Scholar 

  10. Chan KC, Knox WF, Gee JM, Morris J, Nicholson RI, Potten CS, Bundred NJ (2002) Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer Res 62:122–128

    PubMed  CAS  Google Scholar 

  11. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Steward A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM (2004) Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1140–1142

    Article  Google Scholar 

  12. Davidoff AM, Kerns BJ, Pence JC, Marks JR, Iglehart JD (1991) P53 alterations in all stages of breast cancer. J Surg Oncol 48:260–267

    Article  PubMed  CAS  Google Scholar 

  13. De Potter CR, Schelfhojut AM (1995) The neu-protein and breast cancer. Virchows Arch 426:107–115

    Article  PubMed  Google Scholar 

  14. Done SJ, Eskandarian S, Bull S, Redston M, Andrulius IL (2001) p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast. J Natl Cancer Inst 93:700–704

    Article  PubMed  CAS  Google Scholar 

  15. Dooley WC (2003) Ductal lavage, nipple aspiration, and ductoscopy for breast cancer diagnosis. Curr Oncol Rep 5:63–65

    Article  PubMed  Google Scholar 

  16. Dooley WC, Ljung BM, Veronesi U, Cazzaniga M, Elledge RM, O’Shaughnessy JA, Kuerer HM, Hung DT, Khan SA, Phillips RF, Ganz PA, Euhus DM, Esserman LJ, Haffty BG, King BL, Kelley MC, Anderson MM, Schmit PJ, Clark RR, Kass FC, Anderson BO, Troyan SL, Arias RD, Quiring JN, Love SM, Page DL, King EB (2001) Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst 93:1624–1632

    Article  PubMed  CAS  Google Scholar 

  17. Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 351:1451–1467

    Article  Google Scholar 

  18. Ernster VL, Ballard-Barbash R, Barlow WE, et al (2002) Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 94:1546–1554

    PubMed  Google Scholar 

  19. Fisher B, Anderson S, Tan-Chiu E, Wolmark N, Wickerham DL, Fisher ER, Dimitrov NV, Atkins JN, Abramson N, Merajver S, Romond EH, Kardinal CG, Shibata HR, Margolese RG and Farrar WB (2001) Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 19:931–942

    PubMed  CAS  Google Scholar 

  20. Fisher B, Bryant J, Dignam JJ, Wickerham DL, Mamounas EP, Fisher ER, Margolese RG, Nesbitt L, Paik S, Pisansky TM, Wolmark N (2002) National Surgical Adjuvant Breast and Bowel Project. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 20:4141–4149

    Article  PubMed  CAS  Google Scholar 

  21. Fisher B, Costantino J, Redmond C, et al (1993) Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 328:1581–1586

    Article  PubMed  CAS  Google Scholar 

  22. Fisher B, Costantino JP, Wickerham DL, et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388

    Article  PubMed  CAS  Google Scholar 

  23. Fisher B, Dignam J, Wolmark N, et al (1999) Tamoxifen in Treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353:1993–2000

    Article  PubMed  CAS  Google Scholar 

  24. Fisher B, Dignam J, Wolmark N, et al (1998) Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B17. J Clin Oncol 16:441–452

    PubMed  CAS  Google Scholar 

  25. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N (2001) Prevention of invasive breast cancer in women with ductal carcinoma In situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 28:400–408

    Article  PubMed  CAS  Google Scholar 

  26. Fisher ER, Sass R, Fisher B, Wickerham L, Palik SM (1986) Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 6). I Intraductal carcinoma (DCIS) Cancer 57:197–208

    PubMed  CAS  Google Scholar 

  27. Gandhi A, Holland PA, Knox WF, et al (2000) Effects of a pure antiestrogen on apoptosis and proliferation within human breast ductal carcinoma in situ. Cancer Res 60:4284–4288

    PubMed  CAS  Google Scholar 

  28. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. (2003) Meeting highlights: updated International Expert Consensus on the primary therapy of early breast cancer. J Clin Oncol 21:3357–3365

    Article  PubMed  Google Scholar 

  29. Gompel A, Martin A, Simon P, et al (1996) Epidermal growth factor receptor and c-erB2 expansion in normal breast tissue during the menstrual cycle. Breast Cancer Res Treat 38:227–235

    Article  PubMed  CAS  Google Scholar 

  30. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Dongsheng T, Shepherd LE, Pritchard KJ, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer, M, Pater JL (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 49:793–802

    Google Scholar 

  31. Goulet RJ, Badve L, Brannon-Peppas, et al (2004) Pilot trial assessing the feasibility of intra-ductal delivery of epirubicin (epi)-containing nanoparticules (NP) via InDuct@ Breast Microcatheter (IDBM). Proc Am Soc Clin Oncol 24:83 (abstract 828)

    Google Scholar 

  32. Habel LA, Moe RE, Daling HR, et al (1997) Risk of contralateral breast cancer among women with carcinoma in situ of the breast. Ann Surg 225:69–75

    Article  PubMed  CAS  Google Scholar 

  33. Half E, Tang XM, Gwyn K, Sabin A, Wathen K, Sinicrope FA (2002) Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62:1676–1681

    PubMed  CAS  Google Scholar 

  34. Holland R, Faverly DRR (1997) Whole organ studies. In: Ductal Carcinoma In Situ of The Breast, MJ Silverstein, ed. Williams & Wilkins, Baltimore, MD, pp 238–239

    Google Scholar 

  35. Holland R, Hendriks JHCL, Verbeek ALM, Mravunac M, Schuurmans Stekhoven JH (1990) Extent, distribution, and mammographic/histologic correlations of breast ductal carcinoma in situ. Lancet 335:519–522

    Article  PubMed  CAS  Google Scholar 

  36. Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M; UK Coordinating Committee on Cancer Research; Ductal Carcinoma in situ Working Party; DCIS trialists in the UK, Australia, and New Zealand. (2003) Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362:95–102

    Article  PubMed  Google Scholar 

  37. Howe LR, Subbaramaiah, Patel J, Masferrer JL, Deora A, Hudis C, Thaler HC, Muller WJ, Du B, Brown AMC, Dannenberg AJ (2002) Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)neu-induced breast cancer. Cancer Res 62:5405–5407

    PubMed  CAS  Google Scholar 

  38. Kiljn JGM, Berns PMJ, Schmitz PIM, et al (1992) The clinical significance of the epidermal growth factor (EGFR) in human breast cancer: a review of 5232 patients. Endoc Rev 13:3–17

    Article  Google Scholar 

  39. Lakhani SR, Stratton SR, Poller DN (1997) In Ductal Carcinoma In Situ of The Breast MJ Silverstein, ed. Williams & Wilkins, Baltimore, MD, pp 82

    Google Scholar 

  40. Lam S, MacAulay C, Le Riche JC, Dyachkova Y, et al (2002) A randomizedphase II b trial of anethole dithiolethione in smoking with bronchial dysplasia. J Natl Cancer Inst 94:1001–1009

    PubMed  CAS  Google Scholar 

  41. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lanc TF, Illa T (2001) Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276:18563–18569

    Article  PubMed  CAS  Google Scholar 

  42. Luzzi V, Holtschiag, Watson MA (2001) Technical advance expression profiling of ductal carcinoma in situ by laser capture microdissection and high-density oligonucleotide arrays. Am J Pathol 158:2005–2010

    PubMed  CAS  Google Scholar 

  43. Mauvais-Jarvis P, Baudot N, Castaigne D, Banzet P, Kuttenn F (1986) Trans-4-hydroxytamoxifen concentration and metabolism after local percutaneous administration to human breast. Cancer Res 46:1521–1525

    Google Scholar 

  44. Montvale NJ. Medical Economics Company UK Coordinating Committee on Cancer Research (UKCCCR) (2003) Ductal carcinoma in situ (DCIS) Working Party. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362:95–102

    Article  Google Scholar 

  45. Nakhlis F, Morrow M (2003) Ductal carcinoma in situ. Surg Clin North Am 83:821–839

    Article  PubMed  Google Scholar 

  46. NCCN Practice Guidelines in Oncology-v.3.2003; Non-Invasive Breast Cancer. http://www.nccn.org/physician gls/guidelines.html

    Google Scholar 

  47. O’Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Ki Hong W, Fabian CJ, Sigman CC, Bertagnoli MM, Stratton SP, Lam S, Nelson WG, Meyskens FL, Alberts DS, Follen M, Rustgi AK, Papadimitrakopoulou V, Scardino PT, Gazdar AF, Wattenberg LW, Sporn MB, Sakr WA, Lippman SM, Von Hoff DD (2002) Treatment and Prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 8:314–346

    PubMed  Google Scholar 

  48. Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA (1995) Continued local recurrence of carcinoma 15–25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated by biopsy. Cancer 76:1197–2000

    Article  PubMed  CAS  Google Scholar 

  49. Physicians’ Desk Reference (2001) TheraCys, BCG Live (Intravesical). Physicians’ Desk Reference, 55th edn, Medical Economics Company Montvale, NJ 2001, pp 792–794

    Google Scholar 

  50. Pujol H, Girault J, Rouanet P, et al (1995) Phase 1 study of percutaneous 4-hydroxy-tamoxifen with analyses of 4-hydroxy-tamoxifen concentrations in breast cancer and normal breast tissue. Cancer Chemother Pharmacol 36:493–498

    PubMed  CAS  Google Scholar 

  51. Rouanet P, Linares-Cruz G, Dravet F, et al (2003) Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation. Breast Cancer Res Treat 82(Suppl 1): S169 (abstract 687)

    Google Scholar 

  52. Saloman DS, Brandt R, Ciardiello F, et al (1995) Epidermal growth-factor related peptides and their receptors in human malignancies. Crit Rev Oncol Haematol 19:183–232

    Article  Google Scholar 

  53. Sapino A, Cassoni P, Stalla A, Bussolati G (1998) Oxytocin receptor within the breast: biological function and distribution. Anticancer Res18:2181–2186

    CAS  Google Scholar 

  54. Sauter ER, Ehya H, Schlatter L, MacGibbon B (2004) Ductoscopic cytology to detect breast cancer. Cancer J 10:33–41; discussion 15–16

    Article  PubMed  Google Scholar 

  55. Senn HJ, Thurlimann B, Goldhirsch A, Wood WC, Gelber RD, Coates AS (2003) Comments on the St. Gallen consensus 2003 on the primary therapy of early breast cancer. 12:569–582

    Google Scholar 

  56. Silverstein MJ (ed) (1997) Ductal Carcinoma In Situ of the Breast. Williams & Wilkins, Baltimore, MD

    Google Scholar 

  57. Singh-Ranger G, Mokbel K (2002) The role of cyclooxygenase-2 (COX-2) in breast cancer, and implications of COX-2 inhibition. Eur J Surg Oncol 28:729–737

    Article  PubMed  CAS  Google Scholar 

  58. Solin LJ, Fourquet A, Vicini FA, et al (2001) Mammographically detected ductal carcinoma in situ of the breast treated with breast-conserving surgery and definitive breast irradiation: long term outcome and prognostic significance of age and margin status. Int J Radiat Oncol Biol Phys 50:991–1002

    Article  PubMed  CAS  Google Scholar 

  59. Solin LJ, Kurtz J, Fourquet A, et al (1996) Fifteen year results of breast-conserving energy and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol 14:754–763

    PubMed  CAS  Google Scholar 

  60. Suo Z, Bjaamer A, Ottestad L, Nesland JM (2001) Expression of EGFR family and steroid hormone receptors in ductal carcinoma in situ of the breast. Ultrastruct Pathol 25:349–356

    Article  PubMed  CAS  Google Scholar 

  61. Swain SM (2001) Tamoxifen for patients with estrogen receptor-negative breast cancer. J Clin Oncol 19(Suppl): 93s–97s

    PubMed  CAS  Google Scholar 

  62. Wulfkuhle JD, Sgroi DC, Krutzsch H, McLean K, McGarvey K, Knowlton M, Chen S, Shu H, Sahin A, Kurek R, Wallweiner D, Merino MJ, Petricoin EF, Zhao Y, Steeg PS (2002) Proteomics of human breast ductal carcinoma in situ. Cancer Res 62:6740–6749

    PubMed  CAS  Google Scholar 

  63. Zhang Z, Yamashita H, Toyama T, Hara Y, Omoto Y, Sugiura H, Kobayashi S, Harada N, Iwase H (2002) Semi-quantitative immunohistochemical analysis of aromatase expression in ductal carcinoma in situ of the breast. Breast Cancer Res Treat 74:47–53

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. US Oncology Group, 3535 Worth St. Collins 5, Dallas, TX, 75246, USA

    Joyce A. O’Shaughnessy

Authors
  1. Joyce A. O’Shaughnessy
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Dept. of Medical Oncology, Jules Bordet Institute, Boulevard de Waterloo, 215, 1000, Brussels, Belgium

    Martine J. Piccart MD, PhD  & Fatima Cardoso MD  & 

  2. Anderson Cancer Center, The University of Texas MD, 1515 Holcombe Blvd, Houston, TX, 77030-4095, USA

    Mien-Chie Hung PhD

  3. Dept. of Radiation Oncology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, Pennsylvania, 19104-4283, USA

    Lawrence J. Solin MD

  4. Dept. of Surgery, Emory University Hospital, 1364 Clifton Road NE B206, Atlanta, Georgia, 30322-1059, USA

    William C. Wood MD

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

O’Shaughnessy, J.A. (2006). Ductal Carcinoma In Situ: Systemic Treatment. In: Piccart, M.J., Hung, MC., Solin, L.J., Cardoso, F., Wood, W.C. (eds) Breast Cancer and Molecular Medicine. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-28266-2_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-28266-2_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-28265-5

  • Online ISBN: 978-3-540-28266-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation